CN113304241A - Application of radix stephaniae tetrandrae and radix astragali decoction and components thereof in preparation of anti-myocardial hypertrophy medicines - Google Patents
Application of radix stephaniae tetrandrae and radix astragali decoction and components thereof in preparation of anti-myocardial hypertrophy medicines Download PDFInfo
- Publication number
- CN113304241A CN113304241A CN202110731543.0A CN202110731543A CN113304241A CN 113304241 A CN113304241 A CN 113304241A CN 202110731543 A CN202110731543 A CN 202110731543A CN 113304241 A CN113304241 A CN 113304241A
- Authority
- CN
- China
- Prior art keywords
- decoction
- stephaniae tetrandrae
- radix
- radix stephaniae
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 45
- 206010007572 Cardiac hypertrophy Diseases 0.000 title claims abstract description 40
- 239000009636 Huang Qi Substances 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims description 22
- 229940079593 drug Drugs 0.000 title claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 67
- 235000006533 astragalus Nutrition 0.000 claims abstract description 54
- 241001061264 Astragalus Species 0.000 claims abstract description 44
- 210000004233 talus Anatomy 0.000 claims abstract description 44
- 206010019280 Heart failures Diseases 0.000 claims abstract description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 28
- 230000002829 reductive effect Effects 0.000 claims abstract description 17
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 12
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 12
- 241000132012 Atractylodes Species 0.000 claims abstract description 9
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 8
- 235000006545 Ziziphus mauritiana Nutrition 0.000 claims abstract description 8
- 244000126002 Ziziphus vulgaris Species 0.000 claims abstract description 8
- 235000008529 Ziziphus vulgaris Nutrition 0.000 claims abstract description 8
- 235000008397 ginger Nutrition 0.000 claims abstract description 8
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 8
- 235000011477 liquorice Nutrition 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 238000001914 filtration Methods 0.000 claims abstract description 5
- 244000273928 Zingiber officinale Species 0.000 claims abstract 3
- 239000009330 huangqi decoction Substances 0.000 claims description 13
- 239000003463 adsorbent Substances 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 239000011347 resin Substances 0.000 claims description 7
- 229920005989 resin Polymers 0.000 claims description 7
- 238000001291 vacuum drying Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000013270 controlled release Methods 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 230000002459 sustained effect Effects 0.000 claims description 3
- 238000013268 sustained release Methods 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims 2
- 235000014347 soups Nutrition 0.000 claims 1
- 210000002966 serum Anatomy 0.000 abstract description 19
- 241000045403 Astragalus propinquus Species 0.000 abstract description 10
- 230000004217 heart function Effects 0.000 abstract description 10
- 241001465754 Metazoa Species 0.000 abstract description 7
- 210000005003 heart tissue Anatomy 0.000 abstract description 7
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 7
- 206010061218 Inflammation Diseases 0.000 abstract description 6
- 230000004054 inflammatory process Effects 0.000 abstract description 6
- 238000011161 development Methods 0.000 abstract description 5
- 231100000915 pathological change Toxicity 0.000 abstract description 4
- 230000036285 pathological change Effects 0.000 abstract description 4
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 description 46
- 210000004027 cell Anatomy 0.000 description 33
- 230000002107 myocardial effect Effects 0.000 description 28
- 210000004413 cardiac myocyte Anatomy 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 230000002861 ventricular Effects 0.000 description 9
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 8
- 239000000835 fiber Substances 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 229940039009 isoproterenol Drugs 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 206010020880 Hypertrophy Diseases 0.000 description 6
- 102000004889 Interleukin-6 Human genes 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 6
- 102000017946 PGC-1 Human genes 0.000 description 6
- 108700038399 PGC-1 Proteins 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 229940100601 interleukin-6 Drugs 0.000 description 6
- 210000005240 left ventricle Anatomy 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 5
- 108010082126 Alanine transaminase Proteins 0.000 description 5
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 5
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 5
- 102000003777 Interleukin-1 beta Human genes 0.000 description 5
- 108090000193 Interleukin-1 beta Proteins 0.000 description 5
- 102400001263 NT-proBNP Human genes 0.000 description 5
- 102000000536 PPAR gamma Human genes 0.000 description 5
- 108010016731 PPAR gamma Proteins 0.000 description 5
- 229930040373 Paraformaldehyde Natural products 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 208000033774 Ventricular Remodeling Diseases 0.000 description 5
- 241000234314 Zingiber Species 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 229920002866 paraformaldehyde Polymers 0.000 description 5
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000001969 hypertrophic effect Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000004904 shortening Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 3
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 230000014725 late viral mRNA transcription Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 235000017443 Hedysarum boreale Nutrition 0.000 description 2
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 2
- 101001074444 Homo sapiens Polycystin-1 Proteins 0.000 description 2
- 102000003921 Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha Human genes 0.000 description 2
- 108090000310 Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha Proteins 0.000 description 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 2
- 108010009711 Phalloidine Proteins 0.000 description 2
- 102100036143 Polycystin-1 Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 235000019206 astragalus extract Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000002592 echocardiography Methods 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 2
- 210000002837 heart atrium Anatomy 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000008354 sodium chloride injection Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- 206010072268 Drug-induced liver injury Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 239000012741 Laemmli sample buffer Substances 0.000 description 1
- 241000218164 Menispermaceae Species 0.000 description 1
- 206010028594 Myocardial fibrosis Diseases 0.000 description 1
- 108020001621 Natriuretic Peptide Proteins 0.000 description 1
- 102000004571 Natriuretic peptide Human genes 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 101150004928 bun gene Proteins 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000005189 cardiac health Effects 0.000 description 1
- 230000001269 cardiogenic effect Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000002196 fr. b Anatomy 0.000 description 1
- 210000003918 fraction a Anatomy 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 235000021384 green leafy vegetables Nutrition 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 210000001595 mastoid Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000000692 natriuretic peptide Substances 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the technical field of traditional Chinese medicines, and discloses a radix stephaniae tetrandrae and astragalus decoction and application of components thereof in preparing a medicament for resisting myocardial hypertrophy, wherein the radix stephaniae tetrandrae and astragalus decoction comprises the following raw material components: 50-70g of radix stephaniae tetrandrae, 60-90g of astragalus membranaceus, 35-55g of bighead atractylodes rhizome, 20-40g of liquorice, 35-55g of ginger and 25-45g of Chinese date, and the radix stephaniae tetrandrae and astragalus membranaceus decoction is obtained by decocting the raw materials in water, filtering and concentrating under reduced pressure. Dispersing radix Stephaniae Tetrandrae and radix astragali decoction with water, sequentially eluting with water, 15-22% ethanol, 35-45% ethanol and 90-100% ethanol, wherein the 35-45% ethanol and 90-100% ethanol eluates are component A and component B of radix Stephaniae Tetrandrae and radix astragali decoction; animal pharmacodynamic studies prove that the radix stephaniae tetrandrae and radix astragali decoction, the component A and the component B can obviously improve the cardiac function level of a heart failure model mouse, reduce serum heart failure markers, relieve inflammatory reaction and improve the pathological change of heart tissues, play an obvious role in resisting the heart failure of the mouse, and have certain development potential in the aspect of preparing medicaments for treating myocardial hypertrophy.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to application of fangji astragalus decoction and components thereof in preparing a medicament for resisting myocardial hypertrophy.
Background
Heart Failure (HF) refers to a group of clinical syndromes in which the function of pumping blood of the Heart is impaired due to structural or functional abnormalities of the Heart caused by various reasons, and is mainly manifested by dyspnea, fluid retention, physical weakness, and the like. Ventricular remodeling is an important process for the occurrence and development of heart failure, and myocardial hypertrophy is one of the key pathological links in the process of ventricular remodeling. Myocardial hypertrophy (myocardiac hypertrophy), which is a decompensated response caused by excessive activation or long-term overload of the heart, is an important stage in the development of many heart diseases, and is manifested by enlargement of cardiomyocytes, increase of protein synthesis, promotion of interstitial fibrosis, and the like. Persistent pathological myocardial hypertrophy leads to ventricular dilation, decreased contractile function, and imbalance in energy metabolism, ultimately leading to heart failure. Therefore, improvement of myocardial cell hypertrophy plays an important role in delaying the worsening of heart failure caused by ventricular remodeling. The drug effect substance with the effect of resisting myocardial hypertrophy is researched and screened in the field of traditional Chinese medicines, and has great practical significance and clinical reference value for preventing and treating and improving heart failure diseases.
The active substance of the traditional Chinese medicine is the drug effect basis of the traditional Chinese medicine for preventing and treating various diseases, and how to screen and discover the active component with the effect of resisting myocardial hypertrophy and the preparation thereof from the traditional Chinese medicine and the compound is one of the important research contents of the modernization research of the traditional Chinese medicine.
Fangji Huangqi Tang, as a classic and famous prescription, was recorded in the book of jin Kui Yao L ü e, which is written by Zhang Zhongjing of famous physicians. The traditional Chinese medicine compound consists of four traditional Chinese medicinal materials of radix stephaniae tetrandrae, astragalus, bighead atractylodes rhizome and honey-fried licorice root, and ginger and Chinese date are often added for compatibility in clinic, so that the traditional Chinese medicine compound has the effects of tonifying qi, dispelling wind, strengthening spleen and inducing diuresis. It is clinically used for treating diseases such as cardiogenic edema, hypertension, chronic glomerulonephritis and the like. At present, few studies on myocardial hypertrophy resistance of the medicinal taste of the formula in the tetrandra and astragalus decoction are carried out, and the astragalus extract can obviously inhibit myocardial cell hypertrophy induced by Ang II by down-regulating the expression of PKD1 mRNA (Yang Lei, hair Reynaud, Xuguo Chang. the astragalus extract has the influence on the expression of PKD1 mRNA of mastoid mouse hypertrophic myocardial cells [ J ]. China journal of modern medicine, 2013(08): 12-16.); the astragalus injection can obviously reverse the ATP and calcium ion content in myocardial hypertrophy cells and improve the mitochondrial function (in Yan, Wang Shuoren, Niibo, and the like.) the astragalus injection reverses the influence on the mitochondrial structure and function of myocardial cells in the process of myocardial hypertrophy [ J ].
Chinese traditional medicine J2012, 37(007): 979-984). Cui et al (Cui X H, Wang H L, Wu R, et al. Effect of orthoclades macroperoenols-induced ventricular remodeling in rats [ J ]. Molecular Medicine Reports,2018,17(2).) found that administration of 2.4g/kg/d aqueous decoction of Atractylodis rhizoma inhibited myocardial hypertrophy and myocardial fibrosis by anti-oxidation and inhibition of RAAS activation and thereby reversed ventricular remodeling in mice. Shishirr et al (Shishirr U, oil K.M, Monosha D.Glycyrrhiza glabra (Licorice) root extract obtained from both cardiac activity assays and static the cardiac health in H9c2 cardiac cells [ J ] Journal of Ethnopharmacology,2020,258:112690.) found that aqueous extracts of licorice root had some antioxidant effect and protected cardiomyocytes from DOX-induced toxicity. However, pharmacological research on the anti-heart failure of the compound of the radix stephaniae tetrandrae and astragalus decoction and components thereof is only reported, and no relevant basic research report on the aspect of resisting myocardial hypertrophy is found.
Disclosure of Invention
The invention aims to provide the application of the radix stephaniae tetrandrae and astragalus decoction in preparing the myocardial hypertrophy resistant medicament and provide a brand-new treatment method for heart failure diseases by evaluating the heart failure resistant effect of the radix stephaniae tetrandrae and astragalus decoction and screening and researching drug effect substances for resisting myocardial hypertrophy. Provides scientific basis for the development and utilization of the clinical medicine for treating the heart failure.
In order to achieve the purpose, the invention adopts the technical scheme that:
application of Fangji Huangqi decoction in preparing medicine for resisting myocardial hypertrophy is provided.
In the invention, myocardial hypertrophy refers to the pathological phenomena that cardiac muscle cells are enlarged, protein synthesis is increased, interstitial fibrosis is promoted and the like due to decompensation reaction of the heart caused by various external factors including excessive activation of neuroendocrine factors, long-term overload of the heart, apoptosis, energy metabolism disorder and the like. The invention discloses the application of the radix stephaniae tetrandrae and astragalus decoction in the preparation of the anti-myocardial hypertrophy medicament for the first time, and researches show that the radix stephaniae tetrandrae and astragalus decoction can improve the heart function level of heart failure mice, reduce the relative area of primary myocardial cells and the like, so that the radix stephaniae tetrandrae and astragalus decoction can play the role of resisting myocardial hypertrophy, and can be applied to the preparation of the medicament for treating myocardial hypertrophy.
The radix stephaniae tetrandrae and radix astragali decoction comprises the following raw material components: 50-70g of radix stephaniae tetrandrae, 60-90g of astragalus, 35-55g of bighead atractylodes rhizome, 20-40g of liquorice, 35-55g of ginger and 25-45g of Chinese date.
Preferably, the raw material components of the tetrandra and astragalus decoction comprise: 60g of radix stephaniae tetrandrae, 75g of astragalus, 45g of bighead atractylodes rhizome, 30g of liquorice, 45g of ginger and 36g of Chinese date.
The preparation method of the radix stephaniae tetrandrae and radix astragali decoction comprises the following steps:
a. taking 50-70g of radix stephaniae tetrandrae, 60-90g of astragalus, 35-55g of bighead atractylodes rhizome, 20-40g of liquorice, 35-55g of ginger and 25-45g of Chinese date, and adding water for decoction;
b. filtering the decoction obtained in the step (a), and concentrating under reduced pressure to obtain a paste, namely the tetrandra and astragalus decoction.
The myocardial hypertrophy refers to heart failure. The inventor confirms that the tetrandra and astragalus decoction can obviously improve the heart function level of a heart failure model mouse, reduce serum heart failure markers, relieve inflammatory reaction and improve the pathological change of heart tissues through animal pharmacodynamic research, and plays an obvious role in resisting the heart failure of the mouse.
The dosage of the tetrandra and astragalus decoction for the administration of the myocardial cells is 300-.
The radix stephaniae tetrandrae and astragalus decoction comprises pharmaceutically acceptable medicinal auxiliary materials in traditional Chinese medicine pharmacy, and is prepared into clinical medicament formulations, including tablets, oral liquid, pills, granules, capsules, injections and sustained and controlled release agents.
The invention also provides a component of the radix stephaniae tetrandrae and astragalus membranaceus decoction, which comprises a component A or a component B, and the preparation method of the component A comprises the following steps: dispersing the radix Stephaniae Tetrandrae and radix astragali decoction with water, separating with macroporous adsorbent resin column, sequentially eluting with water, 15-22% ethanol, 35-45% ethanol and 90-100% ethanol, collecting eluates, concentrating the eluates under reduced pressure, and vacuum drying, wherein the eluate of 35-45% ethanol is dried to obtain component A of radix Stephaniae Tetrandrae and radix astragali decoction;
the preparation method of the component B comprises the following steps: dispersing the radix Stephaniae Tetrandrae and radix astragali decoction with water, separating with macroporous adsorbent resin column, sequentially eluting with water, 15-22% ethanol, 35-45% ethanol and 90-100% ethanol, collecting eluates, concentrating the eluates under reduced pressure, and vacuum drying, wherein the 90-100% ethanol eluate is dried to obtain component B of radix Stephaniae Tetrandrae and radix astragali decoction.
The invention also provides application of the tetrandra and astragalus decoction component in preparing a medicament for resisting myocardial hypertrophy. The inventor finds that the radix stephaniae tetrandrae and radix astragali decoction can improve the heart function level of heart failure mice and reduce the relative area of primary myocardial cells, and the like, and the component A and the component B in the eluent also have the effect of reducing the relative area of the primary myocardial cells, which shows that the component of the radix stephaniae tetrandrae and radix astragali decoction can also play the role of resisting myocardial cell hypertrophy, so that the radix stephaniae tetrandrae and radix astragali decoction can be applied to the preparation of the medicament for treating myocardial hypertrophy.
The myocardial hypertrophy is also referred to as heart failure. The inventor also confirms that the components of the tetrandra and astragalus decoction can obviously improve the heart function level of a heart failure model mouse, reduce serum heart failure markers, relieve inflammatory reaction and improve the pathological change of heart tissues through animal pharmacodynamic research, and play an obvious role in resisting the heart failure of the mouse.
Preferably, the preparation method of the component A comprises the following steps: dispersing the radix Stephaniae Tetrandrae and radix astragali decoction with water, separating with macroporous adsorbent resin column, sequentially eluting with water, 20% ethanol, 40% ethanol and 95% ethanol, collecting eluates, concentrating the eluates under reduced pressure, and vacuum drying, wherein the 40% ethanol eluate is dried to obtain component A of radix Stephaniae Tetrandrae and radix astragali decoction;
preferably, the preparation method of the component B comprises the following steps: dispersing the radix Stephaniae Tetrandrae and radix astragali decoction with water, separating with macroporous adsorbent resin column, sequentially eluting with water, 20% ethanol, 40% ethanol and 95% ethanol, concentrating the eluate under reduced pressure, and vacuum drying, wherein the 95% ethanol eluate is dried to obtain component B of radix Stephaniae Tetrandrae and radix astragali decoction.
The dosage of the component A is 6.0-12.5 mug/mL; the dosage of the component B is 15-25 mug/mL.
Similarly, the components of the radix stephaniae tetrandrae and astragalus decoction can comprise pharmaceutically acceptable pharmaceutic adjuvants in traditional Chinese medicine pharmacy, and can be prepared into clinically applicable pharmaceutical formulations including tablets, oral liquid, pills, granules, capsules, injections and sustained and controlled release agents, so that the preparation is convenient to use practically.
The preparation method of the components of the tetrandra and astragalus decoction comprises the following steps:
compared with the prior art, the invention has the following beneficial effects:
(1) the invention provides the application of the radix stephaniae tetrandrae and astragalus membranaceus decoction and the components thereof in the preparation of the anti-myocardial hypertrophy medicines for the first time, and the inventor confirms that the radix stephaniae tetrandrae and astragalus membranaceus decoction can obviously improve the heart function level of a heart failure model mouse, reduce serum heart failure markers, relieve inflammatory reaction, improve pathological changes of heart tissues and play an obvious role in resisting the heart failure of the mouse through animal pharmacodynamics research.
(2) The invention discovers a new application of the tetrandra and astragalus decoction and the components thereof, has a remarkable inhibiting effect on myocardial cell hypertrophy, and the 35-45% ethanol extract and the 90-100% ethanol extract can also be effective components for resisting myocardial cell hypertrophy, and have certain development potential in the aspect of preparing medicaments for treating myocardial hypertrophy.
(3) The preparation method of the radix stephaniae tetrandrae and astragalus membranaceus decoction and the components thereof are simple, the extraction process cost is low, the raw materials are all extracted from traditional Chinese medicinal materials, the traditional Chinese medicinal materials are used as natural medicinal resources, the source is wide, the safety is high, the toxicity is low, the decoction is used as a new raw material for preparing the anti-myocardial hypertrophy medicine, the dosage is low, the curative effect is obvious, and the toxic and side effects are low.
(4) In the animal pharmacodynamic test, the lowest administration doses of the single medicines of the radix stephaniae tetrandrae, the astragalus membranaceus, the bighead atractylodes rhizome and the liquorice are respectively 4g/kg/d, 5g/kg/d, 3g/kg/d and 2g/kg/d, and the administration time of the radix stephaniae tetrandrae and the astragalus membranaceus decoction and the effective components thereof in the cell pharmacodynamic test is only 48h, which are respectively lower than the administration dose and time of the existing research, so that the potential medical value and the good social benefit are achieved.
Drawings
FIG. 1 is an echocardiogram of mice of the control group and the model group in application example 1.
FIG. 2 is the ejection fraction, left ventricular short axis shortening rate and cardiac output of mice to which the control group and the model group of example 1 were applied.
Fig. 3 shows the posterior wall thickness, the ventricular septal thickness, the inner diameter and the volume of the left ventricle at the end systole and the end diastole of the mice of the control group and the model group in the application example 1.
Fig. 4 is an echocardiogram of mice in the control group, model group, low dose group and high dose group in application example 1.
Fig. 5 is a graph showing the ejection fraction, left ventricular short axis shortening rate and cardiac output of the mice in the control group, model group, low dose group and high dose group in application example 1.
Fig. 6 shows the pathological morphology of the myocardial tissues and the deposition of collagen fibers of the mice in the control group, the model group, the low dose group and the high dose group of application example 1.
Fig. 7 shows the area ratio of collagen fibers in the myocardial tissue of mice in the control group, model group, low dose group, and high dose group in application example 1.
FIG. 8 shows the ALT, AST, BUN and Crea contents in blood of mice in the control group, model group, low dose group and high dose group in application example 1.
FIG. 9 shows the control of the concentrations of NT-proBNP and Ang II in the serum of mice in the control group, model group, low dose group and high dose group in application example 1.
FIG. 10 shows the control of the levels of NO, IL-6, IL-1. beta. and TNF-. alpha.in the serum of mice in the control group, model group, low dose group and high dose group of application example 1.
FIG. 11 shows the relative area ratios of cardiomyocytes in primary suckling mice in the control group, model group, positive drug group, and different dosages of Fangji Huangqi Tang group of application example 2.
FIG. 12 is the relative area ratio of the myocardial cells of primary suckling mice of the control group, the model group, the positive drug group, the tetrandra and astragalus decoction component A and the component B in the application example 2.
FIG. 13 shows the relative expression levels of PGC-1. alpha. and PPAR. gamma. proteins in the cardiomyocytes of primary mice in the control group, model group and Fangji Huangqi Tang group of application example 3.
FIG. 14 shows the relative expression levels of PGC-1. alpha. and PPAR. gamma. proteins in the primary mice cardiomyocytes of the control group, the model group, the Fangji Huangqi decoction component A and the component B in application example 3.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail with reference to the following embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention. Those skilled in the art should understand that they can make modifications and equivalents without departing from the spirit and scope of the present invention, and all such modifications and equivalents are intended to be included within the scope of the present invention.
The raw materials used in the following embodiments are all commercially available.
Example 1 preparation of Menispermaceae and Astragalus decoction and Components thereof
60g of radix stephaniae tetrandrae, 75g of astragalus, 45g of bighead atractylodes rhizome, 30g of liquorice, 45g of ginger and 36g of Chinese date are taken and decocted with water; filtering the obtained decoction, and concentrating under reduced pressure to obtain paste, i.e. radix Stephaniae Tetrandrae and radix astragali decoction;
dispersing the paste with water, separating with macroporous adsorbent resin column, sequentially eluting with water, 20% ethanol, 40% ethanol and 95% ethanol, collecting eluates, concentrating the eluates under reduced pressure, and vacuum drying to obtain radix Stephaniae Tetrandrae and radix astragali decoction component A and component B after drying 40% and 95% ethanol eluates.
Application example 1 pharmacodynamic application study of tetrandra and astragalus decoction in resisting heart failure of mice
1. Establishment of Isoproterenol (ISO) induced mouse heart failure model
60C 57 mice are randomly divided into a control group and a model group, the model group is continuously injected with ISO (5mg/kg/d) for 3 weeks to construct a heart failure model, and the control group is injected with 0.9% sodium chloride injection with the same volume subcutaneously. After the molding is finished, performing echocardiography detection on all mice, and regarding the mice with ejection fraction (EF%) < 55% as successful molding.
As shown in fig. 1-3, compared with the control group, after 3 weeks of ISO subcutaneous injection, the heart ejection fraction (EF%), left ventricular short axis shortening rate (FS%) and Cardiac Output (CO) of the mice in the heart failure model group were significantly decreased according to echocardiography (P < 0.01); the posterior wall thickness (LVPW, d; LVPW, s) of the left ventricle at the end stage of systole and diastole is thinned, the ventricular septal thickness (IVS, d; IVS, s) of the left ventricle at the end stage of systole and diastole, the inner diameter (LVID, d; LVID, s) of the left ventricle and the volume (LV Vol, d; LV Vol, s) of the left ventricle at the end stage of systole and diastole are increased to different degrees, so that the structural and functional changes of the left ventricle of the mice in the model group caused by ISO induction are shown, and the successful construction of the heart failure model of the mice is shown.
2. Action of fangji Huangqi decoction on anti-heart failure of mice
The 30 mice in the model group were randomly and evenly divided into three groups, including model group, low dose group and high dose group of Fangji Huangqi Tang. The tetrandra and astragalus decoction (FJHQT) is administrated to mice of a model group by intragastric administration according to clinical equivalent dose of the tetrandra and astragalus decoction, purified water is prepared into suspension, wherein the intragastric administration of a low dose group is 19.4g/kg/d, the intragastric administration of a high dose group is 58.2g/kg/d, the intragastric volume is 0.2mL/10g, and the intragastric administration is continuously carried out for 2 weeks. The control group and the model group were administered with purified water of the same volume by gavage. After the administration, all mice are subjected to echocardiogram detection and data acquisition, and the change of the animal cardiac function before and after the administration is analyzed.
As shown in fig. 4 and 5, after the administration of the tetrandra and astragalus decoction through gastric lavage for 2 weeks, according to the echocardiogram detection result, the heart ejection fraction (EF%), left ventricular minor axis shortening rate (FS%) and Cardiac Output (CO) of the mice in the high dose group and the low dose group are found to have significant return rise, and have statistical difference (P <0.01), which indicates that the tetrandra and astragalus decoction can obviously improve the cardiac function level of the mice with heart failure caused by ISO.
Obtaining animal materials: at the end of the experiment, mice in each group were weighed and recorded and anesthetized by intraperitoneal injection of 15mg/mL sodium pentobarbital (0.7mL/100 g). The mice were fixed in the supine position, and the eyeball was removed to draw blood. The chest is opened, and a small opening is cut in the liver for perfusion. One part of heart for extracting RNA and protein is perfused from the heart to the white liver by using 0.9 percent sodium chloride injection, the heart is cut, blood vessels and redundant tissues on the surface of the heart are removed, the atrium part is quickly cut after water is absorbed by filter paper, the ventricle part is left, the atrium part is immediately placed in dry ice for quick freezing, and then the heart is transferred to a refrigerator at the temperature of minus 80 ℃ for storage; and the other part of the heart is used for pathological tissue section observation, after the heart is perfused by 4 percent paraformaldehyde, the heart is cut, blood vessels and redundant tissues on the surface of the heart are removed, and the heart is fixed in the 4 percent paraformaldehyde.
3. Influence of Fangji Huangqi decoction on heart histopathology of heart failure mice
Staining hearts fixed in 4% paraformaldehyde with hematoxylin and eosin (H.E) to observe pathological morphological changes of mouse myocardial tissues; collagen fiber deposition in myocardial tissue was observed using Masson staining. As shown in fig. 6 and 7, the h.e staining results showed that the control group had well-aligned and compact normal cardiomyocytes, while the heart failure model group mice had disorganized cardiomyocytes and cardiomyocyte fibers in the cardiomyocyte tissue, and enlarged cardiomyocyte gaps; after the administration of the fangji Huangqi decoction, the arrangement disorder of the myocardial cells of the mice in the low-dose group and the high-dose group is improved, and the arrangement disorder of the myocardial cells of the mice in the high-dose group is normal. Masson staining results show that no obvious collagen fiber hyperplasia is seen in the normal myocardial tissues of the control group, the myocardial cell gaps in the myocardial tissues of the model mice with heart failure are increased, the arrangement of the myocardial fibers is disordered, the collagen fibers are obviously proliferated, and the collagen fiber deposition of the low-dose group and the high-dose group is reduced to different degrees after the administration of the radix stephaniae tetrandrae and astragalus decoction.
4. Influence of the decoction of radix Stephaniae Tetrandrae and radix astragali on the serum ALT, AST, Urea and Crea content of heart failure mice
Standing the blood of the mouse at room temperature for 30min, centrifuging at 4 ℃ and 16000g for 10min, sucking the supernatant into a new centrifugal tube, centrifuging at 4 ℃ and 16000g for 10min again, sucking the supernatant into the new centrifugal tube, and freezing the obtained serum at-80 ℃ for later use. Detecting a serum sample by adopting a full-automatic biochemical analyzer, and inspecting the influence of the radix stephaniae tetrandrae and radix astragali decoction on the content of alanine Aminotransferase (ALT), aspartate Aminotransferase (AST), urea nitrogen (BUN) and creatinine (Crea) in a mouse.
As shown in fig. 8, the ALT, AST, Urea indices of each group of mice showed normal, and there was no significant difference between groups. Compared with the control group, the Crea content in the serum of the model group mouse is increased, and the tetrandra and astragalus decoction is reduced in different degrees after administration and tends to be a normal value. The experiment shows that the mice of each group do not have drug-induced liver and kidney injury in the experiment process, the administration dosage is safe, and scientific basis is provided for the safety of the formula for treating the chronic heart failure.
5. Influence of Fangji Huangqi decoction on serum central failure marker NT-proBNP and Ang II content
Thawing frozen serum on ice, and balancing the N-terminal B-type pro-natriuretic peptide (NT-proBNP) enzyme-linked immunosorbent assay kit and the angiotensin II (Ang II) enzyme-linked immunosorbent assay kit for 15-30min at room temperature. And (3) detecting the contents of NT-proBNP and Ang II in the serum according to the steps of the kit specification.
As shown in FIG. 9, the serum concentrations of NT-proBNP and Ang II in the mice in the model group are significantly increased compared with the control group, which indicates that ISO-induced heart failure can cause ventricular dilatation and left ventricular wall pressure increase in the mice, and stimulates the heart to secrete BNP and Ang II, resulting in impaired cardiac function. The concentrations of NT-pro BNP and Ang II in the serum of mice in the high-dose group and the low-dose group of the radix stephaniae tetrandrae and astragalus membranaceus decoction are obviously reduced, which shows that the radix stephaniae tetrandrae and astragalus membranaceus decoction can lower heart failure markers NT-pro BNP and Ang II and improve the cardiac function.
6. The influence of the decoction of radix Stephaniae Tetrandrae and radix astragali on the content of NO, inflammatory factors IL-6, IL-1 beta and TNF-alpha in blood serum
Frozen serum is unfrozen on ice, the content of Nitric Oxide (NO) is detected by adopting a greens method, and the content of interleukin-6 (IL-6), interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha) in the serum is detected by adopting an enzyme linked immunosorbent assay (Elisa).
As shown in FIG. 10, compared with the control group, the serum concentrations of NO, IL-6, IL-1 beta and TNF-alpha in the model group mice are all significantly increased, which indicates that the heart failure of the ISO-induced mice is closely related to the inflammatory reaction. After the high and low doses of the fangji Huangqi decoction are administrated, the concentrations of NO, IL-6, IL-1 beta and TNF-alpha are reduced to different degrees and have obvious differences, which shows that the fangji Huangqi decoction can relieve the inflammatory reaction caused in the process of heart failure.
Extraction and culture of primary suckling mouse myocardial Cells (CMs)
Sterilizing newborn SD suckling mice with 75% alcohol, opening chest, clipping heart, placing in a culture dish containing 1% double-antibody Phosphate Buffered Saline (PBS), cleaning for many times to remove blood, and clipping blood vessel and other redundant tissues. The apex of the heart was excised into an empty petri dish, with one batch of 10 suckling mice hearts each. Cutting heart tissue to 1mm3Size, add a small amount of 1% double antibody in PBS, transfer the small pieces of heart tissue to a 50mL centrifuge tube, gently rest and aspirate as much PBS as possible. Adding 2.5mL of the uniformly mixed digestive juice into a 50mL centrifuge tube containing the cardiac tissue small blocks, placing the centrifuge tube in a 37 ℃ shaking table, oscillating at 200rpm for 45min, and blowing and beating the mixture by using a bent tube for multiple times and uniformly mixing every 15min on average. Digesting until no obvious tissue blocks exist, adding an equal amount of neutralizing solution to stop digestion, uniformly mixing, filtering by a 70-micrometer filter screen, washing the filter screen by using an appropriate amount of neutralizing solution, and collecting filtrate containing cells in a 50mL centrifugal tube. The centrifuge tube containing the filtrate was placed at 4 ℃ and centrifuged at 600g for 5min, and the supernatant was discarded. Adding high-sugar DMEM (Dulbecco's modified eagle medium) into the cell sediment to resuspend the cells, mixing, and inoculating to 75cm2In a culture flask. And (3) after the culture flask is placed in the culture box and the wall is differentially adhered for 30min, the fibroblasts are adhered to the wall in the culture flask, and the cell suspension without adhesion is the myocardial cell suspension. The cardiomyocyte suspension in the culture bottle is sucked into a centrifugal tube, 0.1 percent Brdu (0.1mM) is added to inhibit the growth of fibroblasts, and the plate is placed in a constant-temperature incubator to be incubated until the cardiomyocytes adhere to the wall and have spontaneous pulsation for subsequent experiments. To make the cells adhere more stably, 0.5% gelatin was uniformly pre-plated on the bottom of each well plate before plating, and the gelatin was aspirated after incubation in an incubator at 37 ℃ for 1h for cell plating.
Application example 2 Effect of Fangji Huangqi decoction and its Components on hypertrophic myocardial cells
Primary cardiomyocytes were seeded in 60 wells of a 96-well black board at 5000 cells/well density, and 100. mu.L PBS was added to the remaining wells to avoid edge effects. Placing 96-hole blackboard at 37 deg.C and 5% CO2And incubating for 48h in the cell culture box. Taking out 9Removing culture solution from 6-well blackboard, adding 100 μ L of high-sugar DMEM medium containing 0.1% Brdu into each well, synchronously culturing for 24h, and sucking out the culture medium for later use. The experiment is provided with a control group, a model group, a positive drug group and a sample group, wherein the model group is added with a high-glucose DMEM culture medium containing 100 mu M PE, the positive drug group is added with the high-glucose DMEM culture medium containing 100 mu M PE and 10 mu M captopril, the sample group is respectively added with the high-glucose DMEM culture medium containing 100 mu M PE, different concentrations of radix Stephaniae Tetrandrae and radix astragali decoction (100, 200, 300 and 400 mu g/mL) and different components (12.5 mu g/mL for the component A and 25 mu g/mL for the component B), and after treatment, the pore plate is placed in a cell culture box for incubation for 48 h.
The 96-well blackboard is taken out, the culture solution is sucked off, and PBS is added for rinsing for 3 times and 5 min/time. Add 100. mu.L paraformaldehyde to each well and fix at room temperature for 20 min. The paraformaldehyde is aspirated, and the mixture is rinsed 3 times for 5 min/time with PBS. mu.L of Phalloidin (Alexa Fluor 488Phalloidin-FITC) labeled cardiomyocyte actin F-actin (1:20) was added to each well in the dark at room temperature and incubated for 30 min. After recovering the blotted phalloidin, 50. mu.L of Hoechst (1:10000) labeled cell nucleus is added into each well for incubation for 15min, and PBS is added for rinsing for 3 times for 10 min/time after the Hoechst is discarded. And adding a proper amount of PBS into each hole to keep the cells moist, and storing in dark place. Placing a 96-hole blackboard inThe Pico personal high content imaging analysis system is adopted to automatically collect the fluorescence imageAnd (4) carrying out automatic analysis on the picture by software, and counting the area of the myocardial cells.
As shown in figure 11, the radix stephaniae tetrandrae and radix astragali decoction remarkably reduces the myocardial cell area under the concentration of 300 and 400 mug/mL, and the relative areas are respectively reduced by 24.99 percent and 22.82 percent;
as shown in fig. 12, fraction a and fraction B also significantly reduced cardiomyocyte area by 20.54% and 35.27%, respectively.
Application example 3 the effects of Fangji Huangqi decoction and its components on PGC-1 alpha and PPAR gamma proteins in hypertrophic myocardial cells
Primary cardiomyocytes at 4 × 105Inoculating to 6-well plate at a density of one well and placing at 37 deg.C and 5% CO2The cells are grown in the incubator for 48 h. Taking out the 6-hole plate, discarding the culture solution, adding PBS into each hole, rinsing and completely sucking, adding 2mL of high-glucose DMEM medium containing 0.1% Brdu into each hole, synchronously culturing for 24h, and completely sucking the medium for later use. The experiment is divided into a control group, a model group and different sample groups, wherein the model group is added with a high-sugar DMEM culture medium containing 100 mu M PE, the radix Stephaniae Tetrandrae and radix astragali decoction sample group is added with a high-sugar DMEM culture medium containing 100 mu M PE and 400 mu g/mL radix Stephaniae Tetrandrae and radix astragali decoction, the effective component sample group is respectively added with a high-sugar DMEM culture medium containing 100 mu M PE and 12.5 mu g/mL component A or 25 mu g/mL component B, and after uniform mixing, the 6-pore plate is placed in a cell culture box for incubation for 48 h.
The 6-well plate was removed, the culture medium was discarded, rinsed with an appropriate amount of PBS and aspirated. Add 70. mu.L of protein lysate containing 1% PMSF, 1% protease inhibitor and 1% phosphatase inhibitor to each well, lyse on ice for about 5min, lyse the cells thoroughly with a cell scraper, and draw the cell lysate suspension into a 1.5mL centrifuge tube. The cells were centrifuged at 12000rpm for 10min at 4 ℃ to aspirate the supernatant, and protein quantification was performed by BCA method. Adding a certain amount of loading buffer solution 4X Laemmli Sample buffer (containing 1% beta-mercaptoethanol, 9:1) according to the concentration of a protein Sample, uniformly mixing, putting the protein Sample into a water bath kettle at 100 ℃ to boil for 10min to denature the protein Sample, and putting the protein Sample on ice for cooling. Protein immunoblotting Western blot method was used to detect the expression levels of peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1 alpha), peroxisome proliferator-activated receptor gamma (PPAR gamma), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) proteins.
As shown in fig. 13, the fangji Huangqi decoction can significantly up-regulate the expression of PGC-1 α and PPAR γ proteins in the hypertrophic cardiac muscle cells;
as shown in FIG. 14, component A of the Fangji Huangqi decoction can significantly increase the expression of PGC-1 alpha protein in cardiac muscle cells, and component B can simultaneously increase the expression of PGC-1 alpha and PPAR gamma protein in cardiac muscle cells;
experimental results show that the radix stephaniae tetrandrae and astragalus decoction and the effective components thereof have obvious effect of resisting myocardial hypertrophy. Therefore, the tetrandra and astragalus decoction and the effective components thereof have certain potential in the aspect of treating heart failure diseases.
Claims (10)
1. Application of Fangji Huangqi decoction in preparing medicine for resisting myocardial hypertrophy is provided.
2. The application of the radix stephaniae tetrandrae and radix astragali decoction in preparing the anti-myocardial hypertrophy medicine according to claim 1, wherein the radix stephaniae tetrandrae and radix astragali decoction is prepared from the following raw material components: 50-70g of radix stephaniae tetrandrae, 60-90g of astragalus, 35-55g of bighead atractylodes rhizome, 20-40g of liquorice, 35-55g of ginger and 25-45g of Chinese date.
3. The application of the radix stephaniae tetrandrae and radix astragali decoction in preparing the anti-myocardial hypertrophy medicine according to claim 1 is characterized in that the preparation method of the radix stephaniae tetrandrae and radix astragali decoction comprises the following steps:
a. taking 50-70g of radix stephaniae tetrandrae, 60-90g of astragalus, 35-55g of bighead atractylodes rhizome, 20-40g of liquorice, 35-55g of ginger and 25-45g of Chinese date, and adding water for decoction;
b. filtering the decoction obtained in the step (a), and concentrating under reduced pressure to obtain a paste, namely the tetrandra and astragalus decoction.
4. The use of the tetrandra and astragalus decoction of claim 1 in the preparation of a medicament for resisting myocardial hypertrophy, wherein the myocardial hypertrophy refers to heart failure.
5. The application of Fangji Huangqi Tang in preparing anti-myocardial hypertrophy medicament as claimed in claim 1, wherein the dosage of Fangji Huangqi Tang is 300-400 μ g/mL.
6. The application of the radix stephaniae tetrandrae and radix astragali decoction in preparing the anti-myocardial hypertrophy medicines according to claim 1, wherein the radix stephaniae tetrandrae and radix astragali decoction comprises pharmaceutically acceptable medicinal auxiliary materials in traditional Chinese medicine pharmacy, and is prepared into clinical medicine dosage forms, including tablets, oral liquid, pills, granules, capsules, injections and sustained and controlled release agents.
7. The radix stephaniae tetrandrae and radix astragali soup component is characterized by comprising a component A or a component B, and the preparation method of the component A comprises the following steps: dispersing the radix Stephaniae Tetrandrae and radix astragali decoction with water, separating with macroporous adsorbent resin column, sequentially eluting with water, 15-22% ethanol, 35-45% ethanol and 90-100% ethanol, collecting eluates, concentrating the eluates under reduced pressure, and vacuum drying, wherein the eluate of 35-45% ethanol is dried to obtain component A of radix Stephaniae Tetrandrae and radix astragali decoction;
the preparation method of the component B comprises the following steps: dispersing the radix Stephaniae Tetrandrae and radix astragali decoction with water, separating with macroporous adsorbent resin column, sequentially eluting with water, 15-22% ethanol, 35-45% ethanol and 90-100% ethanol, collecting eluates, concentrating the eluates under reduced pressure, and vacuum drying, wherein the 90-100% ethanol eluate is dried to obtain component B of radix Stephaniae Tetrandrae and radix astragali decoction.
8. The use of the tetrandra and astragalus decoction component of claim 7 in the preparation of a medicament for resisting myocardial hypertrophy.
9. The use of the tetrandra and astragalus decoction component of claim 8 in the preparation of a medicament for resisting myocardial hypertrophy, wherein the dosage of the component A is 6.0-12.5 μ g/mL; the dosage of the component B is 15-25 mug/mL.
10. The application of the radix stephaniae tetrandrae and radix astragali decoction component in preparing the anti-myocardial hypertrophy medicine according to claim 8, wherein the radix stephaniae tetrandrae and radix astragali decoction component comprises pharmaceutically acceptable medicinal auxiliary materials in traditional Chinese medicine pharmacy, and is prepared into clinical medicine dosage forms, including tablets, oral liquid, pills, granules, capsules, injections and slow-release and controlled-release agents.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110731543.0A CN113304241B (en) | 2021-06-30 | 2021-06-30 | Application of radix stephaniae tetrandrae and radix astragali decoction and components thereof in preparation of anti-myocardial hypertrophy medicines |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110731543.0A CN113304241B (en) | 2021-06-30 | 2021-06-30 | Application of radix stephaniae tetrandrae and radix astragali decoction and components thereof in preparation of anti-myocardial hypertrophy medicines |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113304241A true CN113304241A (en) | 2021-08-27 |
CN113304241B CN113304241B (en) | 2022-09-06 |
Family
ID=77381198
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110731543.0A Active CN113304241B (en) | 2021-06-30 | 2021-06-30 | Application of radix stephaniae tetrandrae and radix astragali decoction and components thereof in preparation of anti-myocardial hypertrophy medicines |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113304241B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114668829A (en) * | 2022-04-26 | 2022-06-28 | 北京尚捷优蓝科技有限公司 | Radix stephaniae tetrandrae and radix astragali composition for inhibiting COX-2 activity and preparation method and application thereof |
CN114984087A (en) * | 2021-03-02 | 2022-09-02 | 天津中医药大学 | Traditional Chinese medicine composition, decoction and pharmaceutical composition, and preparation method and application thereof |
CN116077614A (en) * | 2023-01-30 | 2023-05-09 | 青岛市市立医院 | Radix stephaniae tetrandrae and astragalus membranaceus soup and application thereof in protecting renal ischemia reperfusion injury |
CN117243967A (en) * | 2023-11-17 | 2023-12-19 | 细胞生态海河实验室 | Application of Met-tRNAiMet or tRNAiMet in preparation of medicines for treating myocardial hypertrophy and heart failure |
-
2021
- 2021-06-30 CN CN202110731543.0A patent/CN113304241B/en active Active
Non-Patent Citations (2)
Title |
---|
崔昊震等: "防己黄芪汤对离体家兔心房肌收缩力及心房钠尿肽分泌调节的影响", 《延边大学医学学报》 * |
王侠等: "中西医结合治疗高血压左心室肥厚逆转的临床观察", 《山西中医》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114984087A (en) * | 2021-03-02 | 2022-09-02 | 天津中医药大学 | Traditional Chinese medicine composition, decoction and pharmaceutical composition, and preparation method and application thereof |
CN114984087B (en) * | 2021-03-02 | 2023-04-25 | 天津中医药大学 | Traditional Chinese medicine composition, decoction and pharmaceutical composition, and preparation method and application thereof |
CN114668829A (en) * | 2022-04-26 | 2022-06-28 | 北京尚捷优蓝科技有限公司 | Radix stephaniae tetrandrae and radix astragali composition for inhibiting COX-2 activity and preparation method and application thereof |
CN116077614A (en) * | 2023-01-30 | 2023-05-09 | 青岛市市立医院 | Radix stephaniae tetrandrae and astragalus membranaceus soup and application thereof in protecting renal ischemia reperfusion injury |
CN117243967A (en) * | 2023-11-17 | 2023-12-19 | 细胞生态海河实验室 | Application of Met-tRNAiMet or tRNAiMet in preparation of medicines for treating myocardial hypertrophy and heart failure |
CN117243967B (en) * | 2023-11-17 | 2024-01-23 | 细胞生态海河实验室 | Application of Met-tRNAiMet or tRNAiMet in preparation of medicines for treating myocardial hypertrophy and heart failure |
Also Published As
Publication number | Publication date |
---|---|
CN113304241B (en) | 2022-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113304241B (en) | Application of radix stephaniae tetrandrae and radix astragali decoction and components thereof in preparation of anti-myocardial hypertrophy medicines | |
CN111888434B (en) | Anti-coronavirus traditional Chinese medicine granules and preparation method and application thereof | |
CN101721488B (en) | Pharmaceutical composition for treating liver diseases and prepration method thereof | |
CN111773211B (en) | Application of haemagglutinin in preparation of anti-rheumatoid arthritis drugs | |
CN117482131A (en) | Traditional Chinese medicine composition for treating chronic kidney disease and application thereof | |
CN111840425A (en) | Traditional Chinese medicine composition for treating diabetic nephropathy and application thereof | |
US9089577B1 (en) | Water extracts of cinnamon and Radix Astragali | |
CN112587643B (en) | Anti-hepatic fibrosis traditional Chinese medicine compound composition and preparation method thereof | |
CN110742935B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating chronic alcoholic steatohepatitis | |
CN105560265A (en) | Application of bupleurum polysaccharide in preparation of drugs used for preventing and treating diabetic nephropathy | |
CN107737214B (en) | Pharmaceutical composition for treating hepatic fibrosis and preparation method and application thereof | |
CN115624560B (en) | Traditional Chinese medicine active ingredient compound for treating chronic renal failure and application thereof | |
CN105213405A (en) | Dihydrotanshinone I is preparing the application in anti-hepatic fibrosis medicines | |
CN116270787B (en) | Application of Chinese and western compound medicine in preparation of leukemia treatment medicine | |
CN116059292B (en) | Traditional Chinese medicine composition for treating heart failure and preparation process thereof | |
CN103830337A (en) | Chinese medicinal composition for treating chronic alcoholic toxic liver disease | |
WO2014086255A1 (en) | Use of composition of yam polysaccharides and yam proteins | |
CN103550312B (en) | A kind of polygonum capitatum hypoglycemic extractive capsule and preparation method thereof | |
CN102423351A (en) | Channel ushering drug common achyranthes-containing traditional Chinese drug composition for improving bone marrow stem cell homing | |
CN115364168B (en) | Traditional Chinese medicine composition for treating and/or preventing diabetic microvascular complications and/or nerve complications, and preparation method and application thereof | |
CN108159282B (en) | Traditional Chinese medicine composition for treating diabetes complicated with hepatic fibrosis | |
CN108619264B (en) | Ginseng and scutellaria baicalensis capsule and preparation process thereof | |
CN115282150A (en) | Application of fangchinoline in preparation of anti-heart failure medicine | |
CN101099850A (en) | Medicine composition for treating chronic active hepatitis and early-stage hepatocirrhosis and preparation method thereof | |
US9877992B2 (en) | Water extracts of cinnamon and Radix Astragali |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |